A phase II, open-label, multicenter study of futibatinib in patients with iCCA harboring FGFR2 gene fusions or other rearrangements (FOENIX-CCA2) showed that a total of 43 of 103 patients (42%) had a response, and the median DOR was 9.7 months (95% CI 7.6–17.0) [31]. The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.